PAI-1 and Diabetes: A Journey From the Bench to the Bedside
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
D iabetologists have been well awaresince the seminal work ofHimsworth(1) in the 1930s that type 2 (insu-lin resistant) and type 1 (insulin defi-cient) diabetes were distinct entities with different pathophysiological bases. They have been aware for some time that type 2 diabetes is associated with resistance of tissues such as muscle and liver to the biological effects of in-sulin. Furthermore, they knew that type 2 diabetes per se and insulin resistance could both predispose to an increased risk of premature coronary artery dis-ease and particularly the premature oc-currence of myocardial infarction (MI). By contrast, cardiologists came to em-
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another prominent SASP component, PAI-1, is increased in the circulation and tissues, such as coronary arteries of patients with diabetes (57).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939
Writing Committee Members, Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3182051b4c · Cited by 1,873
Hamsten, A., Wiman, B., de Faire, U., & Blombäck, M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512193132501 · Cited by 1,342
Alessi, M. C., Peiretti, F., Morange, P., Henry, M., Nalbone, G., & Juhan-Vague, I. (1997) · Diabetes · doi:10.2337/diab.46.5.860 · Cited by 615 · cited 1×
“Adipose tissue expresses PAI-1 (23) and may be a particularly important source of PAI-1 in blood in obese subjects.”
BackgroundEhrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Self-citationVague, P., Juhan-Vague, I., Aillaud, M. F., Badier, C., Viard, R., Alessi, M. C., & Collen, D. (1986) · Metabolism · doi:10.1016/0026-0495(86)90209-x · Cited by 443
Werf, F. V. D., Ludbrook, P. A., Bergmann, S. R., Tiefenbrunn, A. J., Fox, K. A. A., Geest, H. D., Verstraete, M., Collen, D., & Sobel, B. E. (1984) · New England Journal of Medicine · doi:10.1056/nejm198403083101001 · Cited by 358
Self-citationFactors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients
McGill, J. B., Schneider, D. J., Arfken, C. L., Lucore, C. L., & Sobel, B. E. (1994) · Diabetes · doi:10.2337/diab.43.1.104 · Cited by 310
Self-citationAlessi, M. C., Juhan-Vague, I., Kooistra, T., Declerck, P. J., & Collen, D. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646997 · Cited by 289 · cited 2×
“Triglycerides and their constituents (fatty acids) increase the expression of PAI-1 in HepG2 cells (15).”
BackgroundTissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
Auwerx, J., Bouillon, R., Collen, D., & Geboers, J. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.68 · Cited by 276 · cited 1×
“Results of studies in vivo linking diabetes and insulin resistance to increased expression of PAI-1dElevated concentrations of PAI-1 have been observed consistently in blood from patients with diabetes, particularly those with type 2 diabetes (17).”
Background
Cited by
Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity
Palmer, A. K., Tchkonia, T., LeBrasseur, N. K., Chini, E. N., Xu, M., & Kirkland, J. L. (2015) · Diabetes · doi:10.2337/db14-1820 · Cited by 423
“Another prominent SASP component, PAI-1, is increased in the circulation and tissues, such as coronary arteries of patients with diabetes (57).”
BackgroundHemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation
Spronk, E., Sykes, G., Falcione, S., Munsterman, D., Joy, T., Kamtchum-Tatuene, J., & Jickling, G. C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.661955 · Cited by 225
Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets
Pechlivani, N., & Ajjan, R. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00001 · Cited by 197
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Kearney, K., Tomlinson, D., Smith, K., & Ajjan, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0515-9 · Cited by 130
“Hormonal (hyperinsulinemia) and metabolic (hyperglycemia and hypertriglyceridemia) derangements, typically found in T2DM patients, seem to have a role in elevated levels of PAI-1 levels in this population [130].”
BackgroundDiabetic Vasculopathy: Molecular Mechanisms and Clinical Insights
Jia, G., Bai, H., Mather, B., Hill, M. A., Jia, G., & Sowers, J. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020804 · Cited by 135
“On the one hand, insulin resistance increases plasminogen activator inhibitor-1 (PAI-1) and fibrinogen while decreasing tissue plasminogen activator levels [66].”
BackgroundInfluential
Metadata
- Authors
- Schneider, D. J., & Sobel, B. E.
- Affiliations
- University of Vermont (US)
- Corresponding author
- Schneider, David J.
- ORCID
- Schneider, David J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-09-11
- Volume
- 35
- Issue
- 10
- Pages
- 1961-1967
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3447837
- OpenAlex
- W1974895405
- Cited by
- 78
- References
- 50
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 4 · 2019: 6 · 2018: 6 · 2017: 7 · 2016: 4 · 2015: 8 · 2014: 1 · 2013: 9 · 2012: 2
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- plasminogen activator inhibitor-1, type 2 diabetes, type 1 diabetes, insulin resistance, myocardial infarction, coronary artery disease, cardiovascular risk, thrombosis
- MeSH terms
- Animals, Coronary Artery Bypass, Coronary Artery Disease, Diabetes Mellitus, Type 2, Fibrinolysis, Humans, Insulin, Insulin Resistance, Male, Myocardial Infarction, Obesity, Tissue Plasminogen Activator, Rabbits, Angioplasty, Balloon, Coronary, Randomized Controlled Trials as Topic, Plasminogen Activator Inhibitor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PAI-1 and Diabetes: A Journey From the Bench to the Bedside. https://app.cochat.ai/papers/10.2337/dc12-0638
- The paper
- Schneider, D. J., & Sobel, B. E. (2012). PAI-1 and Diabetes: A Journey From the Bench to the Bedside. Diabetes Care. https://doi.org/10.2337/dc12-0638
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.